Home > Back to Publisher > Report Information

Early Stage and Discovery Deals: Strategy, Structure and Payment Terms 2nd Edition

Innovaro Pharmalicensing
December 1, 2006
144 Pages - SKU: PL1542272

Abstract Table of Contents Related Reports

With deals increasing in terms of number and value, partnering at early stage development is now an integral component of pharmaceutical and biotech business strategy. Pharmalicensing revised and updated early stage report analyzes early stage dealmaking trends and discusses the basics of dealmaking structures, covering payments terms and deal valuations. In-depth contracts, case studies and new deal data allows you to discover the benefits of early stage partnering and review the complex payment structures involved when making an early stage deal.

Please Note: This product is delivered as a zip file.

Table of Contents
Executive summary
Executive summary
1. Introduction
2. What are the benefits of early-stage partnering?: 2.1. The role of partnering in corporate strategy; 2.2. The revenue from in-licensed products is predicted to have an annual growth rate of 10%; 2.3. Partnering for pipeline development
3. The evolving role of partnering in the biotech and pharma industries: 3.1. Licensing to partnering; 3.2. The traditional licensing model; 3.3. The transition from straight-forward transactional exchanges to complex partnering agreements; 3.4. Who benefits from the risk and reward sharing?; 3.5. Sharing knowledge is a big part of the deal structure; 3.6. What does the partnering model teach us?; 3.7. Complex partnering models; 3.8. A shift in early stage dealmaking
4. Early-stage deal strategies and structures: 4.1 Successful out-licensing; 4.2. When do companies partner?; 4.3. Early and late-stage deals - a cost comparison; 4.5. Licensing strategy case studies; 4.6. Deal types
5. Payment strategies: 5.1. Deciding a strategy; 5.2. Payment options
6. How to make the right deal: 6.1. Constructing the deal; 6.2. Finding the right partner; 6.3. Deal timeframes; 6.4. Deal valuation; 6.5. Keeping a deal successful; 6.6. When to negotiate termination; 6.7. What makes a deal ‘newsworthy’?
7. Deal terms and trends - An analysis of early stage deals: 7.1. Why are deal-terms put in the public domain?; 7.2. Does survey data reflect the real deal?; 7.3. Headline valuations; 7.5. Components of the deal
Appendix 1 - Glossary of terms
Appendix 2 - Resources
Appendix 3 - Complex deal terms: an outline
Appendix 4 - Press releases
Appendix 5 - References
Appendix 6 - Biographies: Acknowledgements; Pharmalicensing; Pharmalicensing Order Form
List of Tables: Table 1. GSK’s - Centers of Excellence for Drug Discovery consists of 7 individual centres. 13Table 2. R&D project mathematical valuation models need to be more complex in order to reflect reality.; Table 3. Big pharmas dealmaking trends show that they prefer to invest in similar development stages.; Table 5. The top 5 deal values in Jan 2006 - Oct 2006 combined reached a total of more than $US 1.6 billion.; Table 6. Top 5 upfront payments between Jan-2006 and Oct-2006.; Table 7. The top 5 valued University deals, Jan-2006 to Oct-2006.; Table 8. A summary of different deal types.; Table 8. Payment strategies - components of the deal; Table 9. Variants affecting royalty payments; Table 11. Attributes that attract partners; Table 11. Major early-stage partnering events; Table 12. A selection of networking clubs worldwide; Table 14. Early stage deals deal frames - from contact to signature; Table 15. Factors contributing to deal valuation; Table 16. Ongoing due diligence to keep a deal successful; Table 17. A preclinical project is worth significantly less than a phase I or phase II project.
List of Figures: Figure 1. Amount raised from partnering 1980-2005. 7; Figure 2. Between Jan 2006 - Oct 2006, 6 early stage deals were valued at over $US 100 million.; Figure 3. Deals disclosing upfront payments between Jan 2006-Oct 2006.; Figure 4. The values of University deals are significantly lower than biotech deals between Jan 2006 and Oct 2006.; Figure 6. Key information sources for partnering executives; Figure 7. Lead Molecule R&D projects have increased most in value Jan. 2003 to Oct. 2006.; Figure 8. Breakdown of discovery deals from 2003 to October 2006*; Figure 9. Breakdown of lead discovery deals from 2003 to October 2006*; Figure 10. Preclinical deals from 2003 to October 2006*; Figure 11. Average total upfront payments by stage of development at deal closing ($ million); Figure 13. Average royalty rates by stage of development at deal closing (%)

Early Stage and Discovery Deals: Strategy, Structure and Payment Terms 2nd Edition

Share this report

Other tasks

Research Assistance

Related Markets

Biopharmaceuticals Reports

Free Alert Me service